Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 712

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 2
Chunk 712
---
 (5) nominees named in the Proxy Statement were elected at the Annual Meeting to serve as the Company’s
directors until the Company’s 2025 Annual Meeting of Stockholders and until each of their respective successors are elected
and qualified or until each of their earlier resignation or removal. The final voting results with respect to the election of
each such nominee were as follows:

    Nominee
     
    For
     
    Withheld

    Todd Davis
     
    3,534,258
     
    815

    Ezra Friedberg
     
    3,534,258
     
    815

    Francis Knuettel II
     
    3,534,258
     
    815

    Dr. Richard Malamut
     
    3,534,254
     
    819

    Chia-Lin Simmons
     
    3,532,834
     
    2,239

There
were 415,239 broker non-votes with respect to each such nominee for the first proposal.

Proposal
2 – The amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares authorized
for issuance thereunder was approved by the Company’s stockholders. The final voting results were as follows:

    For
     
    Against
     
    Abstain

    3,527,889
     
    4,985
     
    2,199

There
were 415,239 broker non-votes with respect to the second proposal.

Proposal
3 – The proposal to waive the limit on the number of shares of Common Stock that may be issued to certain shareholders
pursuant to that certain Securities Purchase Agreement, dated July 24, 2024, and that certain Common Stock Purchase Agreement,
dated July 26, 2024, as required by NYSE American, was approved by the Company’s stockholders. The final voting results
were as follows:

    For
     
    Against
     
    Abstain

    3,126,104
     
    406,770
     
    2,199

There
were 415,239 broker non-votes with respect to the third proposal.

Proposal
4 – The reincorporation of the Company in Nevada and simultaneous name change to “Channel Therapeutics Corporation”
was approved by the Company’s stockholders. The final